Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.54 |
| ▸ | ITGAV | P06756 | 6/20 | 0.54 |
| ▸ | THRA | P10827 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | HRH1 | P35367 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 4/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PCNA | P12004 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24486433 | 0.73 | ITGB3 (0.57) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL21100868 | 0.73 | ITGB3 (0.55) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL21101049 | 0.72 | ITGB3 (0.54) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL27446221 | 0.71 | ITGB3 (0.48) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL24486431 | 0.69 | ITGB3 (0.44) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL21064809 | 0.69 | ITGB3 (0.77) | ITGB3ITGAV | |
| SCHEMBL27446344 | 0.68 | ITGB3 (0.46) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL6852167 | 0.68 | ITGB3 (0.60) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL29107238 | 0.67 | ITGB3 (0.61) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL21100942 | 0.67 | ITGB3 (0.70) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | THRB, TSHR, SLC6A2 | ITGB3 12/4885ITGAV 14/4885THRA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.